Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (June 21st Preview)
-
US probes Germany’s drug pricing under Section 301
The U.S. Trade Representative has launched a Section 301 investigation into Germany’s drug pricing policies, arguing the country is effectively leaving the U.S. to shoulder a disproportionate share of global biopharma R&D costs. The probe was announced by USTR ambassador Jamieson Greer, who cited Germany’s move to fast-track legislation aimed at cutting healthcare spending and controlling insurer costs. The agency said it could pursue remedies if it finds Germany’s actions unreasonably impact the U.S., including confidential supplemental discounts or mandatory variable rate rebates. A public hearing is expected on Sept. 22. Germany’s pricing overhaul follows a reported plan earlier this year framed as necessary to address rising deficits at state insurers. Drugmakers have pushed back, including statements tied to Eli Lilly’s CEO David Ricks. The latest U.S. action also followed months of U.S.-Germany discussions, according to government messaging.
-
No Patient Left Behind challenges foreign HTA valuations
A new report from No Patient Left Behind argues that drug value assessments used outside the U.S. in markets such as Canada and Germany undervalue innovative medicines, claiming the process can shortchange societal benefits by as much as 90%. The group says this misleads U.S. policymakers and distorts debate over whether the U.S. overpays for drugs. The report points to quality-adjusted life year assumptions and “willingness-to-pay” thresholds it describes as outdated, and it criticizes HTAs for not capturing broader benefits to families and society—such as quicker return to work and reduced disability costs. It also says decision models may underweight practical factors like administration burden and travel costs. The release aligns with prior arguments from European CEOs at Sanofi and Novartis about the need to better reflect innovation-driven benefits in European HTA outcomes.
-
Safety signal update for T-cell engaging bispecific antibodies
A systematic review and meta-analysis published on PubMed finds that second primary malignant neoplasms (SPMs) occur measurably after T-cell-engaging bispecific antibody therapy used in adult NHL and multiple myeloma. The analysis pooled SPM estimates across 20 studies covering 2,551 patients, using a protocol registered in PROSPERO. Across available follow-up (median 17.4 months), the pooled estimated proportion of total SPMs was 3.5% (95% CI, 1.8–6.9). Disease-specific estimates were 3.8% for NHL and 3.4% for multiple myeloma. The pooled estimate for SPMs leading to treatment discontinuation was 2.2%, and SPMs leading to death were 1.4%. The authors report that exploratory meta-regression did not identify study-level variables associated with total SPM incidence, while emphasizing that relatively short follow-up limits definitive long-term conclusions.
-
Biotech’s next frontier: AI predicts protein-protein interactions at atomic scale
Researchers unveiled a generative AI model designed to predict protein-protein interactions at atomic scale, aiming to improve how scientists identify and engineer binding partners for therapeutic development. Because many drug classes—including antibody therapies and biologics—depend on specific protein interactions, the approach targets a core bottleneck in discovery. The work frames protein-protein interaction prediction as a way to expand options for treating disease by enabling more accurate hypotheses about how proteins physically contact and function together. The article describes the model’s intended use for both prediction and engineering of interaction interfaces. For drug developers, the immediate value is tighter iteration in early-stage target and construct optimization, with the potential to reduce experimental churn during lead identification and preclinical design.
-
Novel biased µ-opioid agonist posts Phase 1 safety data
Early clinical results describe the safety, pharmacokinetics, and pharmacodynamics of SHR8554, a biased µ-opioid receptor agonist evaluated in a Phase I trial. The report positions the program within opioid research focused on achieving analgesia while reducing adverse effects. The article highlights that the Phase I study provides initial evidence about SHR8554’s clinical tolerability and how the compound behaves in the body, including distribution and receptor-signaling characteristics. If subsequent studies confirm an improved benefit–risk profile, biased agonism could support a next wave of pain therapeutics designed to maintain analgesic efficacy with fewer harms.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.